Rita A. Karachun - Oct 28, 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Sr. VP Fince-Global Controller
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Rita Karachun
Stock symbol
MRK
Transactions as of
Oct 28, 2022
Transactions value $
-$3,210,685
Form type
4
Date filed
11/1/2022, 04:36 PM
Previous filing
May 5, 2022
Next filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $0 +17K +41.35% $0.00 58.1K Oct 28, 2022 Direct
transaction MRK Common Stock Options Exercise $0 +15K +25.82% $0.00 73.1K Oct 28, 2022 Direct
transaction MRK Common Stock Sale -$3.21M -32K -43.77% $100.34 41.1K Oct 28, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -17K -100% $0.00* 0 Oct 28, 2022 Common Stock 17K $53.06 Direct F3
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -15K -48.58% $0.00 15.9K Oct 28, 2022 Common Stock 15K $62.07 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.2800 to $100.4700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2 Holdings include shares acquired in dividend reinvestment transactions.
F3 The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
F4 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
F5 The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.